Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (886)	2/6/2006 3:12:10 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

A Small Number of Genes are Sufficient to Classify a Large Number of Unique Toxicological and Pharmacological End-points Using Gene Expression. G Natsoulis - March 8 (1:30pm) iconixpharm.com iconixpharm.com “these signatures are composed of very few genes which is an added bonus for diagnostic device development.” Just sorta fits in there with my interest in glgc and clda. Reminds me a lot of Icoria before they were aquired, (at least partly because of the name, ha)